目前，对lncRNA的研究受到了低通量的限制。最近，CRISPR筛选能够用于识别功能性的lncRNA，不过基于Cas9酶的CRISPR-Cas9系统在DNA水平上编辑基因时 ...

The genome-editing technology can be supercharged by artificial intelligence—and the results are already being felt.

CRISPR-Cas9 is not the first method available to scientists for modifying DNA ... Meganucleases are an example of such unique sequences. The design of such enzymes that can recognize longer DNA ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Scribe reports preclinical data validating CRISPR genome editing and epigenome modifying technologies for addressing ...

-Company announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for the treatment of certain relapsed or refractory (R/R ...

"Unlike the well-known CRISPR gene-editing system, often described as molecular 'scissors,' the newly studied type IV-A CRISPR system does not cut genes. Instead, it uses an RNA-guided 'effector ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

Presentations will showcase the company’s latest advances enabled by its CRISPR by Design TM approach to engineer safer and more effective in vivo genetic medicines for cardiometabolic disease ...